Unknown

Dataset Information

0

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.


ABSTRACT: The efficacy and safety of bevacizumab with modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion (mIFL) in the first-line treatment of metastatic colorectal cancer (mCRC) has not been well evaluated in randomized clinical trials in Chinese patients. We conducted a phrase III trial in which patients with previously untreated mCRC were randomized 2:1 to the mIFL [irinotecan (125 mg/m(2)), leucovorin (20 mg/m(2)) bolus, and 5-fluorouracil intravenous infusion (500 mg/m(2)) weekly for four weeks every six weeks] plus bevacizumab (5 mg/kg every two weeks) group and the mIFL group, respectively. Co-primary objectives were progression-free survival (PFS) and 6-month PFS rate. In total, 214 patients were enrolled. Our results showed that addition of bevacizumab to mIFL significantly improved median PFS (4.2 months in the mIFL group vs. 8.3 months in the bevacizumab plus mIFL group, P < 0.001), 6-month PFS rate (25.0% vs. 62.6%, P < 0.001), median overall survival (13.4 months vs. 18.7 months, P = 0.014), and response rate (17% vs. 35%, P = 0.013). Grades 3 and 4 adverse events included diarrhea (21% in the mIFL group and 26% in the bevacizumab plus mIFL group) and neutropenia (19% in the mIFL group and 33% in the bevacizumab plus mIFL group). No wound-healing complications or congestive heart failure occurred. Our results suggested that bevacizumab plus mIFL is effective and well tolerated as first-line treatment for Chinese patients with mCRC. Clinical benefit and safety profiles were consistent with those observed in pivotal phase III trials with mainly Caucasian patients.

SUBMITTER: Guan ZZ 

PROVIDER: S-EPMC4012268 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.

Guan Zhong-Zhen ZZ   Xu Jian-Ming JM   Luo Rong-Cheng RC   Feng Feng-Yi FY   Wang Li-Wei LW   Shen Lin L   Yu Shi-Ying SY   Ba Yi Y   Liang Jun J   Wang Dong D   Qin Shu-Kui SK   Wang Jie-Jun JJ   He Jing J   Qi Chuan C   Xu Rui-Hua RH  

Chinese journal of cancer 20111001 10


The efficacy and safety of bevacizumab with modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion (mIFL) in the first-line treatment of metastatic colorectal cancer (mCRC) has not been well evaluated in randomized clinical trials in Chinese patients. We conducted a phrase III trial in which patients with previously untreated mCRC were randomized 2:1 to the mIFL [irinotecan (125 mg/m(2)), leucovorin (20 mg/m(2)) bolus, and 5-fluorouracil intravenous infusion (500 mg/m(2))  ...[more]

Similar Datasets

| S-EPMC5764984 | biostudies-literature
| S-EPMC3838846 | biostudies-literature
| S-EPMC8433607 | biostudies-literature
| S-EPMC10807607 | biostudies-literature
| S-EPMC5181797 | biostudies-other
| S-EPMC7640586 | biostudies-literature
| S-EPMC3174848 | biostudies-literature
| S-EPMC9377107 | biostudies-literature
| S-EPMC7038775 | biostudies-literature
| S-EPMC8657606 | biostudies-literature